DRI12544 (18+ years), QUEST (12+ years)

Up to 81% reduction in severe exacerbations^c was observed through Week 24 with DUPIXENT 300 mg Q2W + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (baseline blood EOS ≥300 cells/μL, DRI12544, secondary endpoint).¹

A 48% reduction in severe exacerbations was seen at Week 52 in patients with no biomarker requirement with DUPIXENT 200 mg Q2W + SOC (n=631) vs placebo + SOC (n=317) (rate ratio: 0.52 [95% CI: 0.41, 0.66]) (ITT population, QUEST, primary endpoint).¹

A 46% reduction in severe exacerbations was observed at Week 52 in patients with no biomarker requirement with DUPIXENT 300 mg Q2W + SOC (n=633) vs placebo + SOC (n=321) (rate ratio: 0.54 [95% CI: 0.43, 0.68]) (ITT population, QUEST, primary endpoint).¹

No statistically significant differences were observed during the 52-week treatment period in patients with baseline blood EOS <150 cells/μL taking DUPIXENT 200 mg Q2W or 300 mg Q2W + SOC and in the ≥150 to <300 cells/μL eosinophil subgroup treated with DUPIXENT 200 mg Q2W + SOC vs matching placebo + SOC.^1,9

^cSevere exacerbations were defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or hospitalization or ED visit due to asthma that required systemic corticosteroids.¹